Fennec Pharmaceuticals Inc. Common Stock
FENC
FENC: Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
moreShow FENC Financials
Recent trades of FENC by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by FENC's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Anhydrous sodium thiosulfate and formulations thereof Apr. 04, 2023
-
Patent Title: Anhydrous sodium thiosulfate and formulations thereof Nov. 29, 2022
-
Patent Title: Anhydrous sodium thiosulfate and formulations thereof Apr. 05, 2022
-
Patent Title: Anhydrous sodium thiosulfate and formulations thereof Oct. 06, 2020
Federal grants, loans, and purchases
Followers on FENC's company Twitter account
Number of mentions of FENC in WallStreetBets Daily Discussion
Recent insights relating to FENC
Recent picks made for FENC stock on CNBC
ETFs with the largest estimated holdings in FENC
Flights by private jets registered to FENC